New HIV combo pill tested for rapid start in 100 patients
NCT ID NCT07357584
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a once-daily pill containing doravirine, lamivudine, and tenofovir can quickly control HIV in people who have never taken HIV drugs before. One hundred newly diagnosed adults will take the pill for 48 weeks. The main goal is to see how many have undetectable virus levels at the end of the study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Doravirine/lamivudine/tenofovir disoproxil (Delstrigo) oral tablet
What this could lead to
If successful, this could show that starting this three-drug combination quickly after diagnosis helps control HIV effectively, offering a simple once-daily option for new patients.
What could go wrong
This is a phase 4 trial with only 100 participants, so results may not apply to everyone. As with any HIV treatment, side effects or drug resistance could occur, and the virus may not be fully suppressed in all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fundacion Huesped
Buenos Aires, C1202ABB, Argentina
-
Fundacion IDEAA -Infectologia de atencion ambulatoria
Ciudad Autonoma de Buenos Aire, Buenos Aires, C1405CKC, Argentina
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••